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Calpain 3 is a member of the calpain family of calcium-dependent intracellular proteases. Thirteen years
ago it was discovered that mutations in calpain 3 (CAPN3) result in an autosomal recessive and progres-
sive form of limb girdle muscular dystrophy called limb girdle muscular dystrophy type 2A. While calpain
3 mRNA is expressed at high levels in muscle and appears to have some role in developmental processes,
muscles of patients and mice lacking calpain 3 still form apparently normal muscle during prenatal
development; thus, a functional calpain 3 protease is not mandatory for muscle to form in vivo but it
is a pre-requisite for muscle to remain healthy. Despite intensive research in this ﬁeld, the physiological
substrates of the calpain 3 protein (hereafter referred to as CAPN3) and its alternatively spliced isoforms
remain elusive. The existence of these multiple isoforms complicates the search for the physiological
functions of CAPN3 and its pathophysiological role. In this review, we summarize the genetic and bio-
chemical evidence that point to loss of function of the full-length isoform of CAPN3, also known as
p94, as the pathogenic isoform. We also argue that its natural substrates must reside in its proximity
within the sarcomere where it is stored in an inactive state anchored to titin. We further propose that
CAPN3 has many attributes that make it ideally suited as a sensor of sarcomeric integrity and function,
involved in its repair and maintenance. Loss of these CAPN3-mediated activities can explain the ‘‘progres-
sive” development of muscular dystrophy.
 2008 Elsevier B.V. All rights reserved.1. Introduction LGMD history
Limb girdle muscular dystrophy (LGMD) is a group of progres-
sive muscle diseases, with weakness and wasting affecting pre-
dominantly shoulder and pelvic girdle muscles of both males and
females with clinical onset, in general, in the ﬁrst three decades
[1–4]. The initial clinical description of what is now known as an
LGMD goes back over 100 years when a German neurologist, Wil-
helm Neurich Erb, described a juvenile form of scapulo-humeral
form of muscular dystrophy [5]. In 1954, the term ‘‘Limb Girdle
Muscular Dystrophy” was coined [6], yet since its description and
until recently, it has been plagued by uncertainties and discredita-
tion [7–9].
While Chung and Morton and Jackson and Carey each reported
an autosomal recessive form of LGMD as early as 1959 [10,11], the
ﬁrst reports of an autosomal dominant inheritance go back to 1986
[12,13]. Prompted by the early successes in what later became
known as ‘‘positional cloning”, the dominant and recessive forms
were deﬁned, respectively, as LGMD1 (autosomal dominant inher-
itance) and LGMD2 (autosomal recessive inheritance) withll rights reserved.
eckmann).LGMD2A (OMIM #253600) being the ﬁrst for which a chromo-
somal locus was assigned [14].
Since then close to 20 LGMD loci have been uncovered and of-
ten identiﬁed [3,15–18]. Interestingly the majority of LGMD genes
encode for structural proteins. For example, mutations in several
transmembrane, cytoskeletal proteins have been identiﬁed such
as dysferlin (LGMD2B; OMIM #253601), the four sarcoglycans
(a-, c-, b- or d-sarcoglycan; LGMD2C-F; OMIM #253700,
#608113, #604286 and #601287, respectively) and caveolin 3
(LGMD1C; OMIM #607801). Mutations were also identiﬁed in
other structural proteins linked to the cytoskeleton of the sarco-
mere including telethonin (LGMD2G; OMIM #601954), titin
(LGMD2J; OMIM #608807) and myotilin (LGMD1A; OMIM
#159000). Finally, mutations in a nuclear protein (lamin A/C
(LGMD1B; OMIM #159001) were linked to a form of autosomal
dominant LGMD.
The gene involved in LGMD2A encodes for CAPN3, a member of
the calpain family, a family of said non-lysosomal, soluble cytosolic
calcium-dependent proteases. The name ‘‘calpain” was derived by
contraction of calcium and papain [19], in reference to the require-
ment for calcium and the sequence homology between this other
family of proteases. The calpains were shown to manifest ubiqui-
tous or tissue-speciﬁc expression patterns and have been the sub-
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end of April 2008) with remarkable progress reported in the fourth
FASEB Summer Research Conference on the biology of Calpains in
Health and Disease (July 2007). Most members of this gene family
are thought to be regulatory or ‘‘noble” proteases that do not com-
pletely demolish their substrates but cleave them in a controlled
and limited manner, thereby modulating their function in an irre-
versible fashion. A wide variety of proteins can be cleaved in vitro
by calpains, and ﬁnding their proper physiological substrates is, to
say the least, not an easy task. This situation prevails also for
CAPN3 as one is, almost 20 years after its initial description [20],
still in search of its natural physiological substrates (e.g. [21]).
Noteworthy, CAPN3 is nevertheless the ﬁrst and still the only gene
product of this gene family that was demonstrated to be directly
and causally involved in the etiology of an inherited disease. More-
over, with predominant expression in skeletal muscles [20,22],
CAPN3 is the ﬁrst enzyme to be incriminated in a muscular dystro-
phy (or speciﬁcally in a LGMD). Since then others have joined this
list, such as the E3 ubiquitin ligase Trim32 (LGMD2H; OMIM
#254110, [23]), the glycosyltransferases FKRP (LGMD2I; OMIM
#607155, [24]) or Fukutin (LGMD2M; OMIM #611588, [25,26]),
or the known or putative protein-O-mannosyl-transferase-1
POMT1 (LGMD2K; OMIM #609308, [27]), or O-mannosyl-transfer-
ase-2 (OMIM 607439, coined LGMD2N in [28]). In this report, we
shall discuss CAPN3 in relation to its pathologic and etiologic role
in LGMD2A. Some of the ideas presented here are common to those
of Kramerova et al. [29] and Duguez et al. [30]. Additional support-
ive data was recently published by Chen et al. [31].2. What have we learned from the genetics?
The average overall prevalence for all of the AR forms of LGMD
is estimated to range from 1:15,000 to 1:100,000, and this can vary
extensively between populations [2,32–36], and among these
LGMD2A seems to be the most frequent in deﬁned populations
[3,33,35,37,38], making it the second most frequent autosomal
recessive muscle disease in northeastern Italy after spinal muscu-
lar atrophy [37]. Unlike for cystic ﬁbrosis, there are no particular
mutational CAPN3 hot spots, though some mutations may be more
frequent than others, often reﬂecting ancient founder effects in
consanguineous isolates – new private mutations appear con-
stantly – so that the list of pathogenic variants increases steadily
(see http://www.dmd.nl/CAPN3, version 080404 for a complete
listing; [39]).
Some 440 distinct CAPN3 mutations are known to date (see
http://www.dmd.nl/CAPN3), of which 212 are non-synonymous
amino acid changes, and at least 135 gene-inactivating mutations
resulting, most commonly, in nonsense mediated decay (NMD).
The recognition of LGMD2A patients whose skeletal muscles are
devoid of CAPN3, as they carry two gene-inactivating alleles, al-
lowed one to infer that a lack of CAPN3 (the protease and/or other
functional properties) is pathogenic as it is indispensable for the
maintenance and survival of functional skeletal muscles [40,41].
Pathogenicity was also shown to be associated with loss of ‘‘proper
proteolytic activity” as somemutations have been shown to reduce
the ability of CAPN3 to proteolyze potential substrates such as fo-
drin and HSP60 or to autolytically self-cleave [42–44]. However,
loss of enzymatic activity is not the case for some pathogenic
LGMD2A missense mutations and therefore, it suggests that the
latter may simply prevent substrate speciﬁcity or that CAPN3
may perform other as yet unidentiﬁed non-proteolytic roles (e.g.
[45–47]).
The distribution of these LGMD2A mutations along the gene is
also informative. The CAPN3 gene spans 24 exons spread over 53
(Ensembl ENSG00000092529) to 65 kilobases of genomic DNA(NCBI NC_000015.8) and encodes for a 3316 basepairs long mature
mRNA (Ensembl ENST00000318023; NCBI NM_000070) directing
the synthesis of CAPN3 also known as p94, an 821 amino acid long
full-length protein of 94 kDa possessing three characteristic unique
regions (Fig. 1B): a proline-rich NS domain (N-terminal sequence),
IS1 and IS2 domains (inserted sequences 1 and 2), with IS2 con-
taining a potential nuclear localization signal (NLS) [20]. Obviously
gene invalidating mutations (e.g. frameshift mutations) can fall
anywhere along this gene’s coding exons. It is, in contrast, informa-
tive to consider the distribution of non-synonymous missense
mutations along the CAPN3 polypeptide or 3D structure [46].
One can see, upon plotting this distribution (along a scanning win-
dow of 20 aa), that deﬁned structural regions (in particular, those
associated with the active site of the molecule) seem to have a
higher rate of mutation than others, though at this level of resolu-
tion, mutations seem to present over the entire length of the pro-
tein (Fig. 1A, see also [39]). Thus, domains IIa and IIb are mutation-
rich regions, while in contrast, the CAPN3-speciﬁc sequences IS1
and IS2, encoded, respectively, by exon 6 and exons 15 and 16,
seem relatively poor but not free of such mutations. Of interest,
these unique domains are also not necessary for activation as the
conventional calpains that lack these sequences, still retain activ-
ity, albeit at a higher calcium concentration. This is in line with
the fact that these elements are phylogenetically less conserved
than the rest of the gene: in a 9 species comparison (bovine, dog,
horse, human, macaque, mouse, pig, rat and sheep) of full-length
CAPN3 consensus sequence, there are, respectively, 26/62, 16/63
and 26/76 amino acid substitutions in NS, IS1 or IS2, of which 22,
11 and 23 are non-conservative substitutions, often present as
clusters. This is to be contrasted to 68 changed residues, of which
29 are non-conserved, for the rest of the protein, i.e., the remaining
620 amino acid residues. These CAPN3-speciﬁc domains may thus
tolerate numerous changes without harmful consequences.
At least 10 distinct CAPN3 transcriptional and post-transcrip-
tional isoforms have been described [22,48–50], with splicing iso-
forms involving mostly exons 6, 15 or 16 and thus the
corresponding proteins may lack or contain either or both IS1
and IS2. These isoforms that lack IS1 and IS2 appear to be primarily
important during development and muscle regeneration as they
are not expressed in healthy adult muscle.
Human CAPN3 differs in at least one respect from that of rodent
in that yet another lens-speciﬁc isoform is seen only in rodents
which makes use of an alternative promoter that has been lost dur-
ing evolution in the human lineage [51], and which leads to the
synthesis of a protein that has a different N-terminal peptide lack-
ing the NS domain [50,52,53]. The existence of these various iso-
forms complicates the search for the physiological functions of
CAPN3 as one no longer needs to reason in terms of a single gene
product but of a multiplicity thereof, a difﬁculty further com-
pounded by the possibility of post-translational modiﬁcations
including phosphorylation (D. Goll, personal communication)
and/or tissue-speciﬁcities [22,48–50,54,55]. Thus, with so many
isoforms, is there a particular one that plays a central causal role
in the etiology of LGMD2A? As will be seen further in this review,
genetic evidence allows the designation of one particular suspect.
The fact that IS1 and IS2 [34,45,56] also harbor pathogenic
mutations (including null-type mutations) suggests that it is the
mature full-length product of CAPN3 (i.e., p94 as it was initially
named by its discoverers [20]) that constitutes the (main) etiologic
target of LGMD2A: indeed, these mutations are not likely to affect
the alternatively spliced isoforms lacking these particular se-
quences, leaving only mature full-length CAPN3 as the defective
entity. This is further corroborated by the observation that (i) while
the alternatively spliced isoforms are synthesized during develop-
ment and muscle maturation, they are absent in fully differenti-
ated muscles and (ii) that LGMD2A patients or animal models
Fig. 1. (A) Distribution of evolutionary non-conserved amino acid residues among mammalian mature CAPN3’s (blue) and reported pathogenic LGMD2A missense mutations
(red) using a scanning window and bins of, respectively, 10 and 20 amino acids. (B) Schematic representation of CAPN3 and its diverse protein domains (I–IV) with the three
calpain 3-speciﬁc domains, NS, IS1 and IS2.
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mally constituted muscles, yet the disease settles in progressively
as they grow and age.
3. What have we learned from biochemical or structural
analyses of the calpains?
We shall not detail here all of CAPN3’s known properties, as the
calpains in general, and CAPN3 in particular are discussed in
numerous reviews (e.g. [39,57–61]). We will however highlight
features relevant for the pathophysiological model proposed
herein.
Besides its three unique peptides (NS, IS1 and IS2) and tissue-
speciﬁcity, a number of other distinctive features distinguish
CAPN3 from most of the remaining calpains. Like the ubiquitous
calpains, CAPN3 does bind calcium ions [62,63], but unlike the for-
mer, it works at physiological, submicromolar calcium concentra-
tions, it turns over rapidly and proteolytic activity of CAPN3 is
not inhibited by the ubiquitously expressed protein calpastatin
(the endogenous inhibitor of calpains, which can also be cleaved
by calpain 3; for review see [64]), nor does it form heterodimer
complexes with the small calpain 4 subunit (e.g. [57–59]). Instead
gel-ﬁltration [65] and X-ray diffraction [66] studies suggest that it
seems to form stable homodimers with its catalytic centers falling
on opposite ends of the dimer.
Functional and structural studies enabled the delineation of dis-
tinct protein structural domains, which have been reviewed else-
where [39,46,57,58] as well as the mapping and identiﬁcation of
its inter- and intramolecular autolytic cleavage sites [63,67–69].
From these studies, the activation mechanism has been inferred.
Puriﬁed CAPN3 has a very short half-life of less than 10 min, and
is rapidly degraded through autolysis [70]. Yet it was shown to be
stable within intact, dissected muscle biopsies [71,72] or myoﬁbr-
illar fractions [65]. This latter ﬁnding is likely due to the necessity
for CAPN3 to be anchored to the cytoskeleton of the sarcomere toprevent its degradation through autolysis or by other cellular
proteases.
3.1. The titin connection
While CAPN3 undoubtedly resides in diverse cellular locations,
a preponderance of evidence suggests that the majority of CAPN3
is anchored to the cytoskeleton of the skeletal muscle sarcomere.
Both yeast-two hybrid and immunohistological data suggest that
mature full-length CAPN3 is stored within the sarcomere bound
to the gigantic (1 lm long), elastic and highly modular scaffold
protein, titin (also known as connectin). Titin acts both as a molec-
ular ruler and blueprint for sarcomere assembly, spanning half a
sarcomere from Z-disk to M-line, and as an adjustable molecular
spring central to mechano-transduction of the contracting myoﬁ-
ber (e.g. [73,74]). Noteworthy, both with titin itself (LGMD2J),
and among the many sarcomeric proteins known to bind directly
or indirectly to titin, one can ﬁnd additional members of the LGMD
family such as telethonin (LGMD2G; OMIM #601954) or myotilin
(LGMD1A, OMIM #159000). Binding to mature full-length CAPN3
is mediated through titin’s N2A and M-line speciﬁc sequences
[68,69,75,76]. These in vitro data were conﬁrmed by protein bind-
ing studies [77] and immunohistochemistry that also showed
localization at the Z-line [69,75,78].
Titin, the third most abundant protein in muscle [79], and its
mRNAs are widely more profuse than those of calpain 3 [80].
Hence, it is likely that titin is present within the sarcomere in vast
stoichiometric excess with respect to CAPN3; and as such can
serve as a reservoir for the latter, which would be dispersed
and stored in this dense lattice structure in a presumably inactive
form. Ojima et al. [81] further showed that full-length mature
CAPN3 is incorporated into myoﬁbrils via titin only once the sar-
comere structures are fully mature. It was suggested that titin
binding, through sequences within IS2, overlap with its putative
nuclear localization signal (NLS) that may stabilize CAPN3 and
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cleavage step is required for activation of its function [68,69,82].
Titin binding might thus function in conjunction with IS1 (the
internal auto-inhibitory propeptide) to block the active site of ma-
ture CAPN3 from substrates and inhibitors [82], and perhaps to
assume a role analogous to that of calpastatin, the known physi-
ological inhibitor of the ubiquitous calpains (for review see [64]).
Interestingly, the excision of IS2 makes CAPN3 more stable [76], a
ﬁnding that may point to a ‘‘dual” role for IS2, an inhibitor of
activity at rest and once it is activated, a factor that contributes
to its lability.
Genetic evidence supports this CAPN3-titin connection. Titin
mutations at the M line region of titin, near the CAPN3 binding
sites were shown, when present in a homozygous state, to result
in pathogenic conditions akin to LGMD as well as to a secondary
CAPN3 depletion in patients with tibial muscular dystrophy
(TMD or LGMD2J; OMIM #608807) [83,84]. In mice, mutations
in titin’s N2 line alter CAPN3’s ability to bind to it. This mutation
results in recessive muscular dystrophy with myositis (mdm)
and a secondary reduction of CAPN3 [85], though the pathogenic
signiﬁcance of this secondary CAPN3 defect in the mdm-mouse
is still unclear. To examine the role of CAPN3 in mdm disease
and to better understand the relationship between CAPN3 and
titin, Huebsch et al. crossed the CAPN3 knock-out and CAPN3
overexpressing mouse to the mdm mouse. In these studies it
was demonstrated that when the mdm mutation was placed
on the CAPN3 knock-out background, it did not result in any
change in the progression or severity of the mdm disease; in
other words, lack of CAPN3 when its titin binding sites have
been eradicated does not cause any additional phenotypic dete-
rioration to animals bearing titin mutations. In contrast, overex-
pression of CAPN3 on the mdm background, exacerbated the
mdm disease [86], presumably due to a loss of titin’s ability to
buffer CAPN3. This conclusion was derived from the knowledge
that overexpression of CAPN3 on a wild type background bears
no phenotype [87]. A similar condition caused by a C-terminal
M-line titin deletion resulting in a myopathy with secondary cal-
pain 3 depletion and sarcomere disassembly was recently de-
scribed in humans [84,88]. Thus, these data support the notion
that too much free calpain 3 that is not anchored to titin can
be toxic, and that healthy muscle ﬁbers usually contain excess
titin binding sites to anchor and regulate CAPN3. When loss of
these binding sites occurs through genetic mutation, CAPN3
can be destabilized and the presence of excess CAPN3 can be
toxic to the cell. All these elements point to an active and essen-
tial interaction between titin and CAPN3. Given the fact that the
latter is known to exist as a homodimer and considering the
general topography of the sarcomere, one still needs to deter-
mine how these homodimers bind to titin: for instance, are
the two potential binding sites (one per calpain polypeptide
chain) both utilized, are they bound to a single or to two distinct
molecules, e.g. two adjacent titin chains and if so onto similar
sites?
The high autolytic vulnerability and short half-life of pure
CAPN3 poses another unanswered question, namely what stabi-
lizes the nascent protein during translation on the polysomes?
Could it be that posttranslational modiﬁcations may regulate the
activated structure, or that the nascent polypeptide initially folds
into an inactive conformation, and that external factors such as
chaperones or perhaps one of its interactors are required to allow
it to assume its active structure? Another possibility may be that
translation of CAPN3 mRNA in muscle ﬁbers is carried out on pol-
ysomes that are in close proximity to the sarcomere, where free ti-
tin- (or other as yet unknown) binding sites are present and
available for the timely trapping and protection of these nascent
protease polypeptide chains as they are being synthesized.3.2. Titin, a homeostatic regulator of CAPN3
It is fascinating to ponder how the skeletal muscle ﬁber protects
itself from unwanted potential damaging effects from this essential
protease, which sits there like a Trojan horse, hidden and protected
within the highly structured myoﬁbrillar sarcomeres. If its activity
is not carefully controlled, it can become a ‘‘conveyor of doom” in
the form of unregulated proteolysis; however, it is interesting to
note that if CAPN3 is ablated, one ends with a diseased muscle.
Thus, it is no surprise that the skeletal muscles evolved a high buf-
fering capacity against this delicate but powerful protease, to pre-
serve robust homeostasis, tolerating and coping with large cellular
differences in CAPN3 levels [87].
On one end, assuming that carriers of one null allele effectively
have half the normal amount of CAPN3, this nevertheless leads to
no major consequences as heterozygous individuals having but one
active allele are asymptomatic. Moreover, considering both the
recessive nature of inheritance and the fact that CAPN3 exists as
a homodimer [65,66] (assuming an equal contribution of the pater-
nal and maternal alleles in any given ﬁber), one expects to ﬁnd in
healthy heterozygotes (carrying both a non-synonymous patholog-
ical mutation and a normal allele), the following three populations
of dimeric mature full-length CAPN3 in, respectively, a 1:2:1 ratio:
homodimers of the products of the healthy allele, heterodimers
consisting, respectively, of the products of one mutant and one
wild type allele, and homodimers of the products of the mutant al-
lele. Mutant homodimers will be non-functional, though eventu-
ally also digested, inter-molecularly, by the remaining active
enzyme. Compound heterodimers, in theory, may or may not be
functional, as one might expect occasionally particular mutations
to manifest a dominant negative effect inactivating the normal
function of the heterodimer [18,89]. The fact that no dominant
LGMD2A allele was described suggests that even under the latter
scenario, there remains enough functional (wild type) homodimers
to fulﬁll its essential cellular roles. Thus, even one quarter of the
amount of normally present functional CAPN3 is likely to be fully
compatible with regular muscle function.
On the other end, excess production of CAPN3 in heterozygous
mdm mice (having one wild type and one mutant titin allele) or in
transgenic mice overexpressing this protease is also non-patho-
genic [87]. This can be explained by at least two factors. There ex-
ists a vast reservoir of titin binding sites to sequester and inactivate
the excess CAPN3 [79,86]: given the stoichiometric excess of titin
over CAPN3 molecules [80], there are potentially many more bind-
ing sites than actually covered. To this, we can add the rapid auto-
lytic cleavage of any residual free protease. If this hypothesis is
correct, it implies that the myoﬁbrillar system is extremely well
buffered for both low (at least one quarter of the normal quantity)
and excess amounts of functional CAPN3. This robustness raises
hopes that a misadjusted or even partial therapeutic correction
may nevertheless yield beneﬁcial results.
CAPN3 was also observed in other cellular compartments be-
sides the sarcomere [90,91] such as the subsarcolemmnal mem-
brane, where it can crosstalk with dysferlin [92,93] and cleave b-
catenin [91], or the nucleus, to which it could be mobilized through
its NLS signal in IS2 [20,90]. The interactions with the dysferlin
protein complex may also involve AHNAK, a 700 kDa scaffold pro-
tein that is also a potential CAPN3 substrate [94].
As is the casewith CAPN3within themyoﬁbrillar lattice, it is nec-
essary to properly regulate its proteolytic activity at these cellular
sites, to avoid any unwanted deleterious havoc. By analogy, with
the necessity to ensure proper spatio-temporal regulated control
of CAPN3 activity and the fact that this protease is unaffected by cal-
pastatin, one can surmise that other titin-like factorsmust act to reg-
ulate cytosolic, nuclear and membrane-bound CAPN3 as well. The
identity of these postulatedmolecules is still unknown. Given, how-
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we shall conﬁne our discussion to its role within this structure.4. Physiological role of CAPN3
Numerous studies have been launched to identify substrates of
CAPN3. These shall not be reviewed here. Our focus is to try to infer
from current knowledge of this protease, of its known interactors
and of the sarcomere, where in the muscle ﬁber one needs to look
for these substrates.
Can one attempt, in view of the fact that CAPN3 sits predomi-
nantly within the sarcomere, to reconstruct its possible physiolog-
ical function and role? First of all, a word of caution is needed. It
may be hard to consider a single role for such an essential protein,
even considering, as we do here, exclusively its mature full-length
isoform. This is further substantiated by the observation that path-
ogenesis is observed with both loss and preservation of its proteo-
lytic activity, thus suggesting a complex role for this protein.
Second, numerous arguments suggest a role for CAPN3 in the
maintenance of muscle integrity and function rather than in its
ontogeny, development and maturation: CAPN3-deﬁcient patients
or animal models [2,3,77,95] are born with apparently normal
looking and functional muscles; full-length CAPN3 expression is a
relatively late event during muscle development [51]; and its
assembly into the myoﬁbrils occurs after the sarcomere structures
are fully mature [81]. And yet, CAPN3 appears to also play some
role in development by downregulating membrane-bound b-cate-
nin, as suggested by in vitro and in vivo studies [91]. This cellular
function of CAPN3 is not essential for muscle formation, but it does
impact one phenotypic feature of CAPN3 knock-out muscles: the
nuclear/cytosolic ratio of skeletal muscle ﬁbers [91]. This develop-
mental role is also compatible with the observation that transgenic
mice constitutively overexpressing alternatively spliced embryonic
isoforms of CAPN3 (devoid of either exon 6 or 15), are severely af-
fected, presenting with immature muscles resulting from a devel-
opmental block [87]. These are just examples of specialized,
subcellular roles for CAPN3 or its isoforms, the lack of which can
probably be compensated by redundant proteases that are active
during development. Future investigations are likely to uncover
many more of these specialized roles for CAPN3.
Thus, CAPN3 is tightly associated, in an inactive or autoproteo-
lytically protected form with titin, in the middle of a tightly packed
bundle of myoﬁbrillar proteins where Brownian movement for
proteins the size of CAPN3 is greatly limited [96,97]. From this
we can infer that for a potentially labile enzyme that needs to be
mobilized inside the muscle ﬁbers in order to ﬁnd its natural target
substrates, that the latter cannot be far away from where this pro-
tease is anchored in a stable manner, i.e., within the sarcomere, as
no other (small or large) stable reservoir for CAPN3 has currently
been identiﬁed. To sum up thus far, the anchoring to titin has a tri-
ple function: (1) to keep CAPN3 from autolytically degrading itself
and (2) to maintain it in a proteolytically inactive state, but readily
turned on, and (3) to place it in proximity of its substrates.
We propose that one physiological role for CAPN3 is regulation
of sarcomeric protein turnover and maintenance of structural
integrity of sarcomere structure, in a reactive rather than active
manner. Accordingly, as muscle activity can be damaging (e.g.
[98]), one of mature full-length CAPN3’s main roles may be to rid
the cell of damaged sarcomeric proteins and in this way contribute
to the maintenance of an effectively functioning muscle. The sarco-
mere is composed of the largest polypeptides in the world. These
large proteins constitute, together with other abundant proteins
such as muscle actin and myosin (and other sarcomeric proteins),
a substantial fraction of total muscle protein in an extract. CAPN3
was shown to be able to cleave many of these sarcomeric proteins,both myoﬁbrillar and cytoskeletal types. Fanin et al. for instance,
reported nebulin degradation in healthy control muscle but not
in muscles of any of eight LGMD2A patients tested [42] and myosin
light chain 1 [99], ﬁlamin C [69,100] and titin [69,77] were also
demonstrated to be CAPN3 substrates. All of these proteins are
constituents of the sarcomere, serving either a structural role (neb-
ulin, ﬁlamin and titin) or, as part of the contractile apparatus, a role
in muscle contraction (MLC1); each of these proteins is part of a
highly organized and enmeshed tight structure of the sarcomere.
Let us ﬁrst examine circumstances of muscle function in order
to consider why and under what circumstances CAPN3 would be
called to cleave these proteins. A muscle cell can go through enor-
mous extremes, from total rest to maximal contraction like in a
sprint, marathon or weight lifting (this is not true for cardiac mus-
cles where extremes are not that far off and where mature full-
length CAPN3 is also absent). Thus, these high-molecular weight
molecules constitute particularly sensitive targets for any damage
or hydrolytic cleavage of their polypeptide chains, which could be
induced by the contraction–extension cycles of a functioning mus-
cle. Indeed, these large proteins are not immune to simple shear or
damage, as they are per deﬁnition more vulnerable than others,
simply as a consequence of size (e.g. assuming an average proba-
bility function of hydrolysis per amino acid unit). It is reasonable
to hypothesize that if optimal muscle function could be compatible
with shorter molecules, natural selection would have since long fa-
vored the emergence of such entities. Yet, this did not happen.
Hence, if titin, nebulin and a few other giant polypeptides are
there, it is because they are needed to ensure efﬁcient mechano-
transduction and passive tension, despite their increased inherent
vulnerability and risk for accumulation of breakdown products.
The latter are likely to be generated with regular muscle use or dis-
use, a trend that might even be further exacerbated when muscle
force generation is high, such as during weight lifting (e.g.
[98,101]). Such accidental cleavage can occur anywhere within
the sarcomeric bundle, with two practical consequences: a local
disorganization of the regular lattice structure and the presence
of damaged proteins or fragments thereof. The accumulation of,
the latter, if not removed or replaced, would lead to cellular toxic-
ity and be progressively and incrementally disruptive, leading to a
gradual further disorganization of the sarcomere structure, to sar-
comere fragility and eventually to striated muscles losing their
ability to contract. Sarcomere loss would be a gradual and incre-
mental process over repeated periods of such muscle injuries,
which may explain the progressive nature of the disease. This
pathophysiological model is compatible, on one hand, with the
observation that CAPN3 was shown to promote myoﬁbrillar pro-
tein turnover during sarcomere remodeling in post-natal wild type
muscle [29], and on the other, with reports of lobulated ﬁbers and
disorganized or disrupted myoﬁbrillar structures seen in CAPN3-
deﬁcient muscles [3,42,75,77,102], which once past a certain
threshold, may become the target of uncontrolled protease action
and ultimately lead to sarcomere disassembly and muscular dys-
trophy. Findings of increased heat shock proteins in the insoluble
fraction of CAPN3 knock-out muscles is consistent with an essen-
tial role for this protease in proper protein turnover.
Hence when a molecular damage occurs in myoﬁbrils, it has to
be rapidly repaired and myoﬁbrillar protein turnover must take
place. This involves proteolytic action and degradation followed
by protein replacement. Given its highly structured lattice organi-
zation, sensing and reaching the sites of damage may not be an
easy task for any agent external to the sarcomere. Considering
(1) the greatly reduced diffusion rate within the sarcomere
[96,97], and that (2) tightly packed sarcomeres are inherently rel-
atively resistant to proteolytic action [103], (3) that the latter activ-
ity ought to be precisely localized and ﬁne tuned, this may imply
the necessity for a local loosening of the structure and an appropri-
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that CAPN3 seems well suited to carry out the proposed task: be-
cause of its characteristic features, the presence of mature full-
length CAPN3 may represent the functional compromise between
the necessity for both giant proteins and eventually the dispersal
or removal of toxic breakdown products. First of all, full-length
CAPN3 is a proximity agent. Obviously it cannot be too aggressive
and do more damage than is needed to repair normal functional
wear and tear. This may be one reason why it is so innately unsta-
ble once in a free form. Obviously it would be better if it were not
calcium-activated, which is the case, as calciummay not always be
around at the exact spot where it is needed, and furthermore cal-
cium inﬂuxes may trigger much more general and less controlled
reactions, resulting in large additional pleiotropically negative side
effects that the cell must avoid. Repair proteolysis has to be very
localized. By anchoring CAPN3 to titin, dispersed within the sarco-
mere, one also ensures that CAPN3 release can occur in a timely
fashion at or near the site of molecular injury.
These CAPN3 substrates and their digestion products are toxic
and hence cannot be allowed to accumulate. The resulting frag-
ments need to be removed from within the sarcomere and elimi-
nated, which is not an easy task due to the tightly bound
structure of the sarcomere. This removal can be facilitated if CAPN3
activity results in a transient local loosening of the sarcomere bun-
dle, for instance if it also removed neighboring intact associated
proteins, allowing diffusion of these small cleavage products away
from the sarcomere or by allowing additional proteases to act on
these substrates. CAPN3’s cleavage products can be marked for fur-
ther proteasome-mediated degradation (possibly by the N-end rule
pathway (which selectively degrades proteins that have a basic or
large hydrophobic N-terminal residues); [104]), by E3 ligases such
as Trim32 or MURF-1, which (in the case of MURF-1) is also located
in the sarcomere. E3 ligases are the ﬁnal enzymes in the process of
adding polyubiquitin chains to protein substrates, targeting them
to the proteasome. CAPN3 would thus not only act upstream of
the ubiquitin pathway but be necessary for its ability to eliminate
sarcomeric proteins, as indicated by the reported failure to activate
high-molecular weight Ub-protein conjugates during recovery
upon muscle disuse in CAPN3 knock-out as compared to wild type
mice [29]. This postulated link with the proteasome is compatible
with the fact that the E3 ubiquitin ligase Trim32, when mutated
can also give rise to a LGMD [23]. A cartoon diagram is provided
(Fig. 2) to demonstrate how CAPN3 might function in the sarco-
mere in conjunction with E3 ubiquitous ligases.
The nice property of this model is that it leads to a speciﬁc and
limited chain of events. As hypothesized, CAPN3-mediated proteol-
ysis may also destabilize the complex locally and allow other pro-
teases to enter near the site of injury. In the absence of CAPN3 such
facilitation processes do not occur, preventing the needed repair-
ing step. Now, suppose there is a threshold for the accumulated
amount of incurred damage that needs to be passed before func-
tional physiological consequences become visible. Thus initially,
local unrepaired damage will leave a molecular unhealable scar,
without further major visible consequences, i.e., the rest of the
structure remains unaltered. Then, as more damage is inﬂicted,
the number of such scars increases, passing a critical threshold
wherein there is enough accumulated damage to destabilize part
of the myoﬁbril, that results in the rapidly observable destruction
of the (even disorganized) scaffold. These processes could eventu-
ally trigger inﬂammation, such as that observed in the eosinophilic
myositis, also due to CAPN3 mutations. All of these events, if fur-
ther aggravated, will lead to muscle pathology. Thus, repeated
injuries will eventually lead to accumulation of protein debris,
and result in destruction and dystrophy.
CAPN3 has indeed all the required attributes to be this ‘‘ﬁrst re-
pair factor”, sitting and waiting just like water hoses along thestreets, waiting for ﬁre. . . that does eventually come. There is
apparently never a pool of activated CAPN3, or if any, only in highly
localized foci. But it can be rapidly activated; its stability (ex-
pressed as half-life in vitro) is such that if needed it has the capac-
ity, through autolytic degradation, to turn over rapidly (hence it
makes much sense that its preferred substrate is itself [67,68,70],
even in trans); it works at endogenous calcium concentrations
and thus needs no other activation trigger to start functioning than
to be released from its trap near the site where it has to enter into
limited and controlled action. CAPN3 would thus be the ﬁrst agent
involved in the repair and maintenance of sarcomere integrity, act-
ing possibly upstream of other factors such as E3 ligases (e.g.
Trim32, MURF), that may target the CAPN3 digestion products
for controlled elimination by the proteasome [29], and possibly
the ubiquitous calpains. The recent reports of the association of
eosinophilic myositis with mature full-length CAPN3 mutations
[105] are thus also coherent with the model discussed herein.
Noteworthy also is the reported accumulation of insoluble protein
aggregates in skeletal muscles of CAPN3 knockout mice [29].
Binding to titin need not to be tight or stable. As shown by Oji-
ma et al. [81], CAPN3 can hop during the contraction extension cy-
cle from one titin site to an adjacent one (presumably in cis, i.e.,
along the same titin molecule, but possibly also in trans on an adja-
cent molecule). Thus, adding but a tiny twist to Ojima et al.’s sug-
gestion that CAPN3 senses myoﬁbrillar stretch, we would propose
that it simultaneously senses also its integrity: the propensity of
CAPN3 to switch localization back and forth from the N2A to the
M-line and possibly jump to adjacent sites and/or molecules dur-
ing sarcomere overextension and contraction may facilitate its role
in sensing sarcomere integrity and hence in maintenance of a func-
tional sarcomere structure. When the structure is not properly in
phase, CAPN3 could self-activate and start its repair action. And
when some CAPN3 has been lost through autolysis, local CAPN3
distribution can likewise be rapidly compensated through dis-
placement from neighboring sites.
Whatever the exact role of CAPN3/p94, it is important to deter-
mine the nature of the triggers that make it come loose. Simple ti-
tin damage could be the signal required for CAPN3 release and
action or that it acts as a ruler sensing proper phasing of the sarco-
meric subunits. It is possible that titin per se is not sufﬁcient as a
signal and that it requires other partners or agents or some post-
translational modiﬁcations, but for sure, titin seems to play a key
if not the major role. Titinopathies can also be reviewed under this
new model, as they could affect calpains 3’s binding, release and
availability. Obviously all the above is also compatible with addi-
tional functions for mature full-length CAPN3, such as helping to
control the regular assembly and maintenance of this ladder-like,
array of proteins surrounding or bound to titin. It is clear that
CAPN3 can exist in discreet areas of the cell such as the nucleus
or plasma membrane, and its cellular function at each of these sites
will need to be elucidated. It is tempting to speculate that in these
cellular compartments too, CAPN3 may be involved in proper
maintenance and repair.
5. Conclusions
Genetic evidence points for a major causal role of the mature
full-length CAPN3 in LGMD2A and we hypothesize that it is essen-
tially a reactive one to repair usage-induced erosion, hence pre-
serving myoﬁbril integrity and function. Interestingly, an
analogous proposition was made for another LGMD2 gene, dysfer-
lin, involving in this case membrane repair functions [106], with
the possible participation of AHNAK and CAPN3 [94].
Biochemical and immunohistochemical evidence suggest that
mature full-length CAPN3’s role is mostly conﬁned to the sarco-
mere. CAPN3 is embedded there, inside this structure, like a Trojan
Fig. 2. Calpain 3 may function in conjunction with E3 ubiquitin ligases to mediate sarcomere remodeling. Shown is a cartoon illustrating calpain 3’s role in sarcomere
remodeling. Calpain 3 (red) is anchored to the sarcomere at the N2 line and M line, through its association with titin (not shown). The contractile proteins are highly
organized and entwined and cannot be degraded in the proteasome without the initiating step of proteolytic dissociation of this complex (for simplicity, only actin and
myosin are shown). Data suggest that calpain 3 is one protein that performs the initial proteolytic cleavage that allows E3 ubiquitin ligases to ubiquitinate the peptides and
target them for degradation in the proteasome (see [29]).
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bound and sequestered by titin. Once released, it will start acting,
hydrolyze its substrates, the cytoskeletal and myoﬁbrillar debris,
contribute to relaxation and destabilization of the structure locally
(beyond the effect of the mechanical damage), loosen the residual
sarcomeric constituents, thereby facilitating removal of the debris
and their access to other cellular proteases. To prevent it from
being a Trojan horse, activated free mature full-length CAPN3 has
also a very short lifetime, and it self digests before it can do any
uncontrolled harm.
One testable prediction of the proposed functional model, is
that any mutation abolishing full-length (IS1-containing) CAPN3’s
autoproteolytic lability yet preserving its normal alloproteolytic
activity (just like wild type mature full-length CAPN3), if it can
be generated, will be dominant and lead to a severe phenotype, like
the transgenic mice expressing IS1- or IS2-less CAPN3 isoforms
[87], possibly incompatible with life even in utero.
All the above does not imply that CAPN3 has no direct role in
other cellular compartments in the cytosol or nucleus. Its nuclear
role (or perhaps that of one of its autolytic degradation products)
may be to induce the repair processes to replace the damaged
and missing sarcomeric elements or regulate transcription factors
[69,90]. But whatever the additional location it has to act in, it will
be imperative to control its relatively rapid turnover rate and inhi-
bit its unwanted effects. These activities are deﬁnitely not incom-
patible with the proposal as gatekeeper of sarcomere functional
integrity. But it will be important to identify what stabilizes CAPN3
in the nucleus or other cellular compartments. The road towards
the unraveling of the calpain mystery is long and fascinating.Acknowledgments
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